Ongericimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase I drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ongericimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ongericimab overview
Ongericimab (JS-002) is under development for the treatment of homozygous familial hypercholesterolemia, heterozygous non-familial and familial hypercholesterolemia, hyperlipidemia, mixed dyslipidemia and hepatocellular carcinoma, lung cancer, transitional cell carcinoma (urothelial cell carcinoma). The drug candidate is administered by subcutaneous and intravenous route. It acts by targeting proprotein convertase subtilisin kexin 9 (PCSK9).
Shanghai Junshi Biosciences overview
Shanghai Junshi Biosciences (Junshi Biosciences) is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is focused on investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple-negative breast cancer, small cell lung cancer. The company is also evaluating JS002 against hyperlipidaemia; JS103 for hyperuricacidemia and gout disease; UPB1211 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS010 for migraine; and JS016 against COVID-19. It operates research and development centers in California and Maryland, the US. Junshi Biosciences is headquartered in Shanghai, China.
For a complete picture of Ongericimab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
